Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students.

BACKGROUND University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity. METHODS EBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay. RESULTS Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (P < .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8(+) T-cells but not in numbers of CD4(+) T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8(+) lymphocytosis (P = .0003). CONCLUSIONS Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8(+) lymphocytosis correlated with disease severity.

[1]  H. Balfour,et al.  Primary Epstein-Barr virus infection does not erode preexisting CD8+ T cell memory in humans , 2012, The Journal of experimental medicine.

[2]  H. Balfour,et al.  Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections , 2011, Clinical Microbiology Reviews.

[3]  K. Fink,et al.  Contribution of Herpesvirus Specific CD8 T Cells to Anti-Viral T Cell Response in Humans , 2010, PLoS pathogens.

[4]  R. Welsh,et al.  Heterologous immunity between viruses , 2010, Immunological reviews.

[5]  D. Thorley-Lawson,et al.  The Dynamics of EBV Shedding Implicate a Central Role for Epithelial Cells in Amplifying Viral Output , 2009, PLoS pathogens.

[6]  J. Altman,et al.  Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. , 2008, Immunity.

[7]  H. Balfour Epstein-Barr virus vaccine for the prevention of infectious mononucleosis--and what else? , 2007, The Journal of infectious diseases.

[8]  Abdul Salam Jarrah,et al.  BIOINFORMATICS ORIGINAL PAPER doi:10.1093/bioinformatics/btm044 Systems biology Simulating Epstein-Barr virus infection with C-ImmSim , 2022 .

[9]  A. Rickinson,et al.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. , 2007, Annual review of immunology.

[10]  M. Melbye,et al.  The epidemiology of EBV and its association with malignant disease , 2007 .

[11]  Bernard Roizman,et al.  Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis , 2007 .

[12]  A. Swerdlow,et al.  A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Richard C Brundage,et al.  A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. , 2005, The Journal of infectious diseases.

[14]  A. Swerdlow,et al.  The immune response to primary EBV infection: a role for natural killer cells , 2005, British journal of haematology.

[15]  L. Meyer,et al.  CD8+ T Cells Specific for EBV, Cytomegalovirus, and Influenza Virus Are Activated during Primary HIV Infection1 , 2004, The Journal of Immunology.

[16]  S. L. Silins,et al.  Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. , 2001, Blood.

[17]  J. Parkin,et al.  A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. , 2001, AIDS research and human retroviruses.

[18]  G. Ogg,et al.  Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo , 1998, The Journal of experimental medicine.

[19]  B. Griffin Relation of Burkitt's tumor‐associated herpes‐type virus to infectious mononucleosis , 1998, Reviews in medical virology.

[20]  L. Gissmann,et al.  Subclinical Epstein-Barr virus infection of both the male and female genital tract--indication for sexual transmission. , 1992, The Journal of investigative dermatology.

[21]  S. Lemon,et al.  A SECOND SITE FOR EPSTEIN-BARR VIRUS SHEDDING: THE UTERINE CERVIX , 1986, The Lancet.

[22]  H. Penman NEOPLASIA AND NEOPLASMS , 1985, The Lancet.

[23]  P. Levine,et al.  Early primary infection and high Epstein‐barr virus antibody titers in greenland eskimos at high risk for nasopharyngeal carcinoma , 1984, International journal of cancer.

[24]  N. Day,et al.  Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study - a review. , 1975, IARC scientific publications.

[25]  V. Diehl,et al.  Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[26]  W. Henle,et al.  Immunofluorescence, interference, and complement fixation technics in the detection of the herpes-type virus in Burkitt tumor cell lines. , 1967, Cancer research.

[27]  M. Epstein,et al.  VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. , 1964, Lancet.